Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) rose 2.1% to $6.83, after the company disclosed that it has completed a licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome in dogs. Share volume was 1.1 million, compared to an all-day average of 8.7 million
